Covaxin offers protection against double mutant (B.1.617) variant
A preprint of the study carried out by ICMR and Bharat Biotech researchers has been posted in biorXiv. Preprints are
Read MoreA preprint of the study carried out by ICMR and Bharat Biotech researchers has been posted in biorXiv. Preprints are
Read MoreA large percentage of those aged 18-44 years does not have the resources to pay for vaccines and hence will
Read MoreWhile Maharashtra is still reporting the most cases daily, there has been a slip dip in the last few days.
Read MoreThe statement tried to address the controversy over whether the price of the vaccines at Rs 600 (nearly $8) per
Read MoreSince April 1, the number of daily cases has been accelerating at a rapid speed. Can it be any reason
Read More“A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered
Read More“Both Covishield vaccinated sera and convalescent sera were found to offer protection against the double mutant variant (B.1.617),” says Dr.
Read MoreThe April 19 announcement of the roll-out of vaccines in the third phase, wherein anyone above 18 years is eligible
Read MoreIn a press release, the EMA said that it found “possible link to very rare cases of unusual blood clots
Read MorePrecious time was wasted before critical facilities began to be scaled up to meet the demands of the second wave
Read MoreIn a meeting held on March 24, the Subject Expert Committee of the India drug regulator permitted Bharat Biotech to
Read MoreWhen do you think the second wave is likely to peak? And when we see such a peak, what do
Read MoreThe vaccines that would be eligible for the fast-track approval will include those that have been granted an EUA by
Read More